Long title
A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 (19CP02) in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r NHL) (CP0201-NHL)
Date receipt dossier
EudraCT number
2023-503830-27, 2022-502661-23-00
Company / Sponsor
Galapagos NV
Phase
I/II
Treated organism
Humans
Indication category
Cancer therapy
Disease
relapsed/refractory B-cell non-Hodgkin lymphoma (r/r NHL)
Therapeutic approach
Immunotherapy
Genetic modification
BCMA CAR
Method of transfer of nucleic acid of interest
Lentiviral vector
Administered biological material
Autologous T cells transduced with lentiviral vectors expressing BCMA-CAR
Route of administration
Intravenous
Locations in Belgium
UZ Leuven, AZ Delta
Nr of subjects
45
Foreseen duration
1/9/2021-1/9/2031
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
GLPG5101 (19CP02)